



Bharat Parenterals Limited

Registered Office & Works:

Survey No.: 144-A, Jarod-Samlaya Road, Vill. Haripura,
Ta. Savli, Dist. Vadodara - 391520 (Guj.) India.

Mobile : 99099 28332

E-mail: info@bplindia.in, Web.: www.bplindia.in

CIN NO: L24231GJ1992PLC018237

(WHO-GMP CERTIFIED ★ STAR EXPORT HOUSE)

Date: July 30, 2025

To,
Secretary
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Scrip Code: 541096

Dear Sir/Madam,

Sub: Innoxel Lifesciences Pvt. Ltd Subsidiary Company of Bharat Parenterals Limited, Received Establishment Inspection Report (EIR) from the U.S. FDA

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform that the Subsidiary Company of Bharat Parenterals Limited Namely, **Innoxel Lifesciences Pvt. Ltd.**, has received the **Establishment Inspection Report (EIR)** from the **United States Food and Drug Administration (U.S. FDA)** for its finished dosage manufacturing facility in Vadodara, Gujarat. Company has successfully cleared United States Food and Drug Administration (U.S. FDA) inspection which was conducted between April 28, 2025 to May 2, 2025 at its manufacturing facility in Vadodara, Gujarat.

Please find the enclosed Company statement titled "**Innoxel Lifesciences Receives Establishment Inspection Report (EIR) from U.S. FDA**"

The Company is committed to maintain the highest quality standards and compliance at all times.

We request you to kindly take the same on record.

Thanking You,

For, **Bharat Parenterals Limited**

Sharmin Soni
Company Secretary & Compliance
M.No: A-75694



Bharat Parenterals Limited

Registered Office & Works:

Survey No.: 144-A, Jarod-Samlaya Road, Vill. Haripura,
Ta. Savli, Dist. Vadodara - 391520 (Guj.) India.

Mobile : 99099 28332

E-mail: info@bplindia.in, Web.: www.bplindia.in

CIN NO: L24231GJ1992PLC018237

(WHO-GMP CERTIFIED ★ STAR EXPORT HOUSE)

Press Release

Bharat Parenterals Limited

Innoxel Lifesciences Receives Establishment Inspection Report (EIR) from U.S. FDA

Vadodara, India, July 30, 2025

Bharat Parenterals Limited is delighted to announce that its subsidiary, **Innoxel Lifesciences Pvt. Ltd.**, has received the **Establishment Inspection Report (EIR)** from the **United States Food and Drug Administration (U.S. FDA)** for its finished dosage manufacturing facility in Vadodara, Gujarat.

This follows the successful completion of the U.S. FDA inspection conducted from April 28 to May 2, 2025.

The facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms – Liquid Injectables and Oral Liquids.

With the receipt of the EIR, Innoxel Lifesciences has also received acceptance of the site for commercial operations for the product(s) under inspection. This milestone reinforces Innoxel's commitment to global quality benchmarks and enhances its capability to supply high-quality pharmaceutical products to regulated markets, such as United States and the European Union.

About Bharat Parenterals Limited

Bharat Parenterals Limited is a leading pharmaceutical company engaged in the manufacturing and marketing of quality pharmaceutical formulations across domestic and international markets. Through its subsidiary, Innoxel Lifesciences Pvt. Ltd., the company focuses on sterile injectable and complex dosage forms for regulated markets.